Mondobiotech Holding AG Company presentation

Licensed Products
• Secretin to Lung Rx LLC
Indication: Methicillin-Resistant Staphylococcus Aureus in Cystic Fibrosis (MRSA in CF)
Milestones: US$ 100’000 signing-up, US$ 1m end of phase II; US$ 10m marketing authorization
Royalties: 10% on net sales
Status: pre-clinical development in-vitro
Lung Rx has returned back to mondoBIOTECH the IP rights, know-how and data on this MPC in May 2011,
together with the Aviptadil platform for strategic reasons. Nevertheless, during 2009 Lung Rx was performing
very early pre-clinical development activities in-vitro and the results did not support further pre-clinical and
clinical development plans for the targeted indication through the targeted mechanism of action.
• Interferon-gamma to InterMune (ITMN)
Indication: Idiopathic Pulmonary Fibrosis (IPF)
Status: Phase 3
IP rights for 5 European countries were licensed and then sold to Intermune. Intermune was solely responsible
for development and dismissed the project in 2007, after performing 2 large Phase III studies delivering INF-γ to
the IPF patients via subcutaneous administration. We recently approached Intermune to inquire possibilities of
collaboration, but they refused. Given existing freedom to operate and based on internal know-how on the drug
and on key confidential data, we intend to start Phase II development of this drug through a different and, in
our and our Community’s belief, more suitable way of administration for IPF.
54